SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-351483
Filing Date
2021-12-08
Accepted
2021-12-08 16:33:32
Documents
12
Period of Report
2021-12-02
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d212365d8k.htm   iXBRL 8-K 22921
  Complete submission text file 0001193125-21-351483.txt   141473

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA itci-20211202.xsd EX-101.SCH 2933
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20211202_lab.xml EX-101.LAB 17373
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20211202_pre.xml EX-101.PRE 10980
5 EXTRACTED XBRL INSTANCE DOCUMENT d212365d8k_htm.xml XML 3214
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 211479098
SIC: 2834 Pharmaceutical Preparations